The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India, the pharmaceutical company stated.

Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cells. It treats lymphoma, myeloma, leukemia, breast cancer and ovarian cancer.

Cyclophosphamide Capsules had annual sales of $6 million in the United States (IQVIA MAT October 2023).

"The group now has 383 approvals and has so far filed over 448* ANDAs since the commencement of the filing process in FY 2003-04,” Zydus Lifesciences said in a statement.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company consolidated net profit surged 53.2% to Rs 800.7 crore in Q2 FY24 as compared with Rs 522.5 crore posted in Q2 FY23. Revenue from operations rose 9.1% YoY to Rs 4,368.8 crore during the quarter ended 30 September 2023.

The scrip was up 0.05% to currently trade at Rs 642.15 on the BSE.